Pharmacology
Pegylated interferon offers several advantages over standard interferon
Published in Hepatitis Weekly, December 8th, 2003
According to a study from Spain, "modification of the pharmacokinetic profile of interferon-alpha (IFN-alpha) through pegylation (addition of a polyethylenglicol molecule) has resulted in a marked improvement of drug efficacy for the treatment of infection due to hepatitis C virus. Two pegylated derivatives of IFN-alpha are available: PEG-IFN-alpha-2a, with a 40-kDa polyethylenglicol molecule of branched structure, and PEG-IFN-alpha-2b, with a 12 kDa linear PEG."
"Both compounds have slower absorption, more reduced distribution and lower elimination rate than the respective...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2003-12-08)
More Articles from Hepatitis Weekly
- Liver Disease
Chronic hepatitis C progression to cirrhosis associates with iron accumulation - Liver Toxin
Some non-steroidal anti-inflammatory drugs have a higher risk for liver injury - Adverse Drug Effects
Interferon therapy for HCV-infected patients warrants psychological assessments - Immunology
Serum soluble Fas levels rise in advanced stages of HCV-induced liver disease - Transplant Medicine
Hepatitis C virus-positive renal donations heighten mortality risk - Autoimmune Recurrence
Post-kidney transplant ANCA-positive glomerulonephritis may be treatable - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
